A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
- 13 September 2012
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 27 (11) , 1373-1378
Abstract
Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder SocietyKeywords
This publication has 15 references indexed in Scilit:
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 2011
- Priorities in Parkinson's disease researchNature Reviews Drug Discovery, 2011
- The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primatesMovement Disorders, 2010
- Molecular mechanisms of L-DOPA-induced dyskinesiaNature Reviews Neuroscience, 2008
- Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]Neurology, 2006
- The hyperkinetic abnormal movements scale: A tool for measuring levodopa-induced abnormal movements in squirrel monkeysMovement Disorders, 2002
- The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson's diseaseMovement Disorders, 1999
- Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)Movement Disorders, 1995
- Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated MonkeysClinical Neuropharmacology, 1993
- Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeysPsychopharmacology, 1990